search
Back to results

Effects of Continuous Dexmedetomidine Infusion on Systemic Microvascular Function in Laparoscopic Cholecystecthomy

Primary Purpose

Laparoscopic Surgery

Status
Recruiting
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
dexmedetomidine intravenous infusion
0.9%sodium chloride
Sponsored by
National Institute of Cardiology, Laranjeiras, Brazil
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Laparoscopic Surgery focused on measuring dexmedetomidine, microcirculation, general anesthesia, central alpha-2 agonists, tissue perfusion

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patients of both sexes (age ≥ 18 and ≤ 60 years)
  • Physical state ASA I or II according to the criteria of the American Association of Anesthesiology
  • Planned surgery of cholecystectomy by videolaparoscopy

Exclusion Criteria:

  • Patient's refusal to participate in the study
  • Inflammation or infection in the sublingual mucosa
  • Emergency surgery
  • Grade III obesity (BMI ≥39.9 kg/m2)
  • Pregnancy or lactation
  • Autoimmune diseases, malignant neoplasms

Sites / Locations

  • Eduardo TibiriçáRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

dexmedetomidine intravenous infusion

0.9% saline solution intravenous infusion

Arm Description

Patients who will receive continuous intraoperative infusion of dexmedetomidine hydrochloride (0.5 µg/kg/h).

Patients who will receive continuous infusion of 0.9% saline solution (sham group).

Outcomes

Primary Outcome Measures

change in microvascular flow index
sublingual microvascular density

Secondary Outcome Measures

Full Information

First Posted
June 22, 2021
Last Updated
June 6, 2022
Sponsor
National Institute of Cardiology, Laranjeiras, Brazil
search

1. Study Identification

Unique Protocol Identification Number
NCT04946396
Brief Title
Effects of Continuous Dexmedetomidine Infusion on Systemic Microvascular Function in Laparoscopic Cholecystecthomy
Official Title
Evaluation of the Effects of Continuous Dexmedetomidine Infusion on Systemic Microvascular Function in Patients Undergoing Laparoscopic Cholecystecthomy: a Prospective Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 1, 2022 (Actual)
Primary Completion Date
August 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Institute of Cardiology, Laranjeiras, Brazil

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The microcirculation represents the primary site of exchange of oxygen and nutrients for tissues, and the preservation of microcirculatory perfusion is essential for the maintenance of organ function. The microcirculation is extremely dynamic and may vary according to the individual's temperature, systemic blood pressure, the use of medications, during physical and mental activity, age and pathological processes. In this context, the development of portable microscopes for clinical use has made possible the non-invasive visualization of the microcirculation and tissue perfusion in patients undergoing several highly complex procedures in cardiology, including cardiac surgery with cardiopulmonary bypass, ECMO (Extracorporeal Membrane Oxygenation) and in critically ill patients in intensive care. CytoCam, for example, is a handheld device that incorporates a darkfield incident light illumination system with a series of high-resolution lenses that project images to a computer dedicated to the system. Dexmedetomidine is a selective agonist of 2-adrenergic receptors in the central nervous system, whose administration results in a reduction in the activity of the sympathetic nervous system and a reduction in the systemic release of catecholamines. Its use in the perioperative period has several beneficial effects, such as reducing neuroendocrine and hemodynamic responses due to anesthesia and surgery, through induction of sedation and analgesia, in addition to reducing the consumption of opioids and anesthetics in general. Several recent studies report that the use of dexmedetomidine in the perioperative period reduces the incidence of postoperative complications, reduces the time on mechanical ventilation and attenuates the neuroendocrine response due to surgical trauma and extracorporeal circulation in patients undergoing cardiac surgery. However, the effects of dexmedetomidine on systemic microcirculation function during its use in anesthesia for elective surgical procedures of medium complexity are not yet known. In conclusion, the hypothesis of the present study is that continuous intravenous infusion of dexmedetomidine during balanced general anesthesia increases the microvascular perfusion flow rate in the sublingual mucosa, representing an increase in systemic microvascular perfusion.
Detailed Description
CytoCam, is a handheld device that incorporates a darkfield incident light illumination system with a series of high-resolution lenses that project images to a computer dedicated to the system. Dexmedetomidine is a selective agonist of 2-adrenergic receptors in the central nervous system, whose administration results in a reduction in the activity of the sympathetic nervous system and a reduction in the systemic release of catecholamines. Its use in the perioperative period has several beneficial effects, such as reducing neuroendocrine and hemodynamic responses due to anesthesia and surgery, through induction of sedation and analgesia, in addition to reducing the consumption of opioids and anesthetics in general. Several recent studies report that the use of dexmedetomidine in the perioperative period reduces the incidence of postoperative complications, reduces the time on mechanical ventilation and attenuates the neuroendocrine response due to surgical trauma and extracorporeal circulation in patients undergoing cardiac surgery. However, the effects of dexmedetomidine on systemic microcirculation function during its use in anesthesia for elective surgical procedures of medium complexity are not yet known. In conclusion, the hypothesis of the present study is that continuous intravenous infusion of dexmedetomidine during balanced general anesthesia increases the microvascular perfusion flow rate in the sublingual mucosa, representing an increase in systemic microvascular perfusion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Laparoscopic Surgery
Keywords
dexmedetomidine, microcirculation, general anesthesia, central alpha-2 agonists, tissue perfusion

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients will be randomized into two groups of 35 patients each: 1) patients who will receive continuous intraoperative infusion of dexmedetomidine hydrochloride (0.5 µg/kg/h) (DEX group) or 2) control group, patients who will receive continuous infusion of 0.9% saline solution (CONT group).
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
70 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
dexmedetomidine intravenous infusion
Arm Type
Experimental
Arm Description
Patients who will receive continuous intraoperative infusion of dexmedetomidine hydrochloride (0.5 µg/kg/h).
Arm Title
0.9% saline solution intravenous infusion
Arm Type
Sham Comparator
Arm Description
Patients who will receive continuous infusion of 0.9% saline solution (sham group).
Intervention Type
Drug
Intervention Name(s)
dexmedetomidine intravenous infusion
Intervention Description
Dexmedetomidine intravenous infusion during laparoscopic cholecystecthomy
Intervention Type
Drug
Intervention Name(s)
0.9%sodium chloride
Intervention Description
0.9%sodium chloride intravenous infusion during laparoscopic cholecystecthomy
Primary Outcome Measure Information:
Title
change in microvascular flow index
Description
sublingual microvascular density
Time Frame
during surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients of both sexes (age ≥ 18 and ≤ 60 years) Physical state ASA I or II according to the criteria of the American Association of Anesthesiology Planned surgery of cholecystectomy by videolaparoscopy Exclusion Criteria: Patient's refusal to participate in the study Inflammation or infection in the sublingual mucosa Emergency surgery Grade III obesity (BMI ≥39.9 kg/m2) Pregnancy or lactation Autoimmune diseases, malignant neoplasms
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
EDUARDO TIBIRICA, MD, PhD
Phone
+55-21-99914-6075
Email
etibi@uol.com.br
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
EDUARDO TIBIRICA, MD, PhD
Organizational Affiliation
National Institute of Cardiology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Eduardo Tibiriçá
City
Rio de Janeiro
ZIP/Postal Code
22240006
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eduardo Tibiriçá, MD, PhD
Phone
21999146075
Email
etibi@oul.com.br

12. IPD Sharing Statement

Learn more about this trial

Effects of Continuous Dexmedetomidine Infusion on Systemic Microvascular Function in Laparoscopic Cholecystecthomy

We'll reach out to this number within 24 hrs